Consumer willingness to pay for a hypothetical Chagas disease vaccine in Brazil: a cross-sectional study and the implications
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Chagas disease is a serious public health problem, endemic in 21 countries in Latin America. A future vaccine can contribute to decreasing the number of cases and its complications. Methods: A cross-sectional study was conducted with residents of the northern region of Brazil, on the willingness to pay for a hypothetical vaccine against Chagas disease (effective protection of 80%). Results: We interviewed 619 individuals and seven were excluded from the analysis and the value of willingness to pay was US$23.77 (100.00 BRL). Conclusion: The Northern region of Brazil is one of the largest markets for this vaccine, due to its epidemiological relevance, so economic studies with this vaccine will be important to assist in the assessment of technologies.
Supplementary Material
File (suppl_file.pdf)
- Download
- 108.79 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
OPAS. Tropical Diseases (2018). www.paho.org/bra/index.php?option=com_joomlabook&view=topic&id=57&ite.mid=232
2.
Brasil. Doenças Negligenciadas (2013). https://agencia.fiocruz.br/doenças-negligenciadas
3.
Drugs for Neglected Diseases Initiative. Neglected Patients (2019). www.dndial.org/
4.
Fundação Oswaldo Cruz. Conheça as principais doenças tropicais negligenciadas (2012). www.fiocruz.br/ioc/cgi/cgilua.exe/sys/start.htm?infoid=1585&sid=32
5.
Albuquerque MAC, Dias DM, Vieira LT, Lima CA, da Silva AM. Mortality Trends for Neglected Tropical Diseases in the State of Sergipe, Brazil, 1980–2013. Infect. Dis. Poverty 6(1), 20 (2017).
6.
Brasil. Doença de Chagas: o que é, causas, sintomas, tratamento e prevenção (2020). https://saude.gov.br/saude-de-a-z/doenca-de-chagas
7.
Lidani KCF, Andrade FA, Bavia L, Damasceno FS, Beltrame MH, Messias-Reason IJ, Sandri TL. Chagas disease: from discovery to a global health problem. Front. Public Health 7, 166 (2019).
• Important to complement our knowledge of Chagas disease.
8.
OPAS. Paraguay interrupts Chagas disease transmission at home (2018). www.paho.org/bra/index.php?option=com_content&view=article&id=5736:paraguai-interrompe-transmissao-vetorial-domiciliar-de-doenca-de-chagas&Itemid=812
9.
Drugs for Neglected Dieseases Initiative. Chagas disease (2019). www.dndial.org/doencas/doenca-chagas/
• Important to complement our knowledge of Chagas disease.
10.
Pérez-Molina JA, Molina I. Chagas disease. Lancet 391(10115), 82–94 (2018).
•• Important to complement our knowledge of Chagas disease.
11.
Fundação Oswaldo Cruz. Conheça as principais doenças tropicais negligenciadas, Doença de Chagas (2012). www.fiocruz.br/ioc/cgi/cgilua.exe/sys/start.htm?infoid=1585&sid=32
12.
Tzizik DM, Borchardt RA. Chagas disease: an under-recognized diagnosis. JAAPA 31(12), 30–33 (2018).
13.
Sala de Apoio a Gestão Estratégica. Número de óbitos por doenças infecciosas e parasitárias (2018). https://sage.saude.gov.br/#
14.
Jones K, Versteeg L, Damania A et al. Vaccine-linked chemotherapy improves benznidazole efficacy for acute Chagas disease. Infect Immun. 86(4), e00876–17 (2018).
15.
Beaumier CM, Gillespie PM, Strych U, Hayward T, Hotez PJ, Bottazzi ME. Status of vaccine research and development of vaccines for Chagas disease. Vaccine 34(26), 2996–3000 (2016).
• Important reference source associated with the development of vaccines for Chagas disease.
16.
Villanueva-Lizama LE, Cruz-Chan JV, Aguilar-Cetina ADC et al. Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico. PLOS Neglect. Trop. Dis. 12(1), e0006240 (2018).
• Important reference source associated with the development of vaccines for Chagas disease.
17.
Rodríguez-Morales O, Monteón-Padilla V, Carrillo-Sánchez SC et al. Experimental vaccines against Chagas disease: a journey through history. J. Immunol. Res. 2015, 489758 (2015).
18.
Gupta S, Garg NJ. A Two-component DNA-prime/protein-boost vaccination strategy for eliciting long-term, protective T cell immunity against Trypanosoma cruzi. PLoS Pathog. 11(5), e1004828 (2015).
19.
Gupta S, Salgado-Jiménez B, Lokugamage N, Vázquez-Chagoyán JC, Garg NJ. TcG2/TcG4 DNA vaccine induces Th1 immunity against acute Trypanosoma cruzi infection: adjuvant and antigenic effects of heterologous T. rangeli booster immunization. Front. Immunol. 10, 1456 (2019).
20.
Barry MA, Versteeg L, Wang Q et al. A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl. Trop. Dis. 13(5), e0007413 (2019).
21.
Brasil. Câmara de Regulação do Mercado de Medicamentos (CMED) (2020). http://portal.anvisa.gov.br/cmed
22.
Brasil. Registros de novos medicamentos: saiba o que é preciso (2020). http://portal.anvisa.gov.br/noticias/-/asset_publisher/FXrpx9qY7FbU/content/registro-de-novos-medicamentos-saiba-o-que-e-preciso/219201
23.
Brasil. Resolução CMED n° 2, de 5 de março de 2004 (2004). http://portal.anvisa.gov.br/documents/374947/2932039/Resolu%C3%A7%C3%A3o+n%C2%BA+2%2C+de+5+de+mar%C3%A7o+de+2004.pdf/d50ebc85-5971-4981-bd16-b619780e6df5
24.
Brasil. Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde (CONITEC), a comissão (2020). http://conitec.gov.br/entenda-a-conitec-2
25.
Machado CV, Lima LD, Baptista TWF. Health policies in Brazil in contradictory times: paths and stumbling blocks in the construction of a universal system. Rep. Public Health 33(Suppl. 2), e00129616 (2017).
26.
Oliveira GLA, Guerra Junior AA, Godman B, Acurcio FA. Cost–effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. Expert Rev. Pharmacoecon. Outcomes Res. 17(2), 109–119 (2017).
27.
Lemos LLP, Guerra Júnior AA, Santos M et al. The assessment for disinvestment of intramuscular interferon Beta for relapsing-remitting multiple sclerosis in Brazil. PharmacoEconomics 36(2), 161–173 (2018).
28.
Instituto Brasileiro de Geografia e Estatística. População (2020). www.ibge.gov.br/apps/populacao/projecao/index.html?utm_source=portal&utm_medium=popclock&utm_campaign=novo_popclock
29.
Mould Quevedo JF, Hernández IC, Espinosa JG, Escudero GS. The willingness-to-pay concept in question. Public Health J. 43(2), 352–358 (2009).
• Important to complement our knowledge of willingness to pay (WTP) approach.
30.
Muniz Júnior RL, Godói IP, Reis EA et al. Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications. Expert Rev. Pharmacoecon. Outcomes Res. 19(4), 473–482 (2019).
• Important to complement our knowledge of WTP approach.
31.
Sarmento TTR, Godói IP, Reis EA, Godman B, Ruas CM. Consumer willingness to pay for a hypothetical chikungunya vaccine in Brazil and the implications. Expert Rev. Pharmacoecon. Outcomes Res. (2019).
•• Important to complement our knowledge of WTP approach.
32.
Haab TC, McConnell KE. Valuing Environmental and Natural Resources. Edward Elgar Publishing Limited, UK (2002).
•• Important to complement our knowledge of WTP approach.
33.
Godói IP, Santos AS, Reis EA et al. Consumer willingness to pay for Dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil; implications for future pricing considerations. Front. Pharmacol. 8, 41 (2017).
34.
Palanca-tan R. The demand for a dengue vaccine: a contingent valuation survey in Metro Manila. Vaccine 26(7), 914–923 (2008).
35.
Hadisoemarto PF, Castro MC. Public acceptance and willingness-to-pay for a future dengue vaccine: a community-based survey in Bandung, Indonesia. PLoS Negl. Trop. Dis. 7(9), e2427 (2013).
36.
Lee JS, Mogasale V, Lim JK et al. A multi-country study of the household willingness-to-pay for Dengue vaccines: household surveys in Vietnam, Thailand, and Colombia. PLoS Negl. Trop. Dis. 9(6), e0003886 (2015).
37.
Ughasoro MD, Esangbedo DO, Tagbo BN, Mejeha IC. Acceptability and willingness-to-pay for a hypothetical Ebola virus vaccine in Nigeria. PLOS Negl. Trop. Dis. 9(6), e0003838 (2015).
38.
Cameron MP, Newman PA, Roungprakhon S, Scarpa R. The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine 31(36), 3712–3717 (2013).
39.
Morey ER, Sharma VR, Mills A. Willingness to pay and determinants of choice for improved malaria treatment in rural Nepal. Soc. Sci. Med. 57(1), 155–165 (2003).
40.
Jimoh A, Sofola O, Petu A, Okorosobo T. Quantifying the economic burden of malaria in Nigeria using the willingness to pay approach. Cost. Eff. Resour. Alloc. 5(6), 1478–7547 (2007).
41.
Udezi WA, Usifoh CO, Ihimekpen OO. Willingness to pay for three hypothetical malaria vaccines in Nigeria. Clin. Therapeut. 32(8), 1533–1544 (2010).
42.
Tawiah T, Malam K, Kwarteng A et al. Improving the first-line treatment of febrile illnesses in Ghana: willingness to pay for malaria rapid diagnostic tests at licensed chemical shops in the Kintampo area. Cost Eff. Resour. Alloc. 16, 4 (2018).
43.
Sadar A, Muhammad RY, Azhar A, Waqas M, Gill BA. Willingness to pay for vaccination against hepatitis b and its determinants: the case study of an industrial district of Pakistan. Epidemiol. Biostat. Public Health 15, 4 (2018).
44.
Instituto Brasileiro de Geografia e Estatística. Estimativas da população residente com data de referência em 1° de julho de 2019 (2019). https://central3.to.gov.br/arquivo/461424/
45.
Atlas de desenvolvimento humano no Brasil. Perfil (2013). www.atlasbrasil.org.br/2013/pt/perfil
46.
Instituto Brasileiro de Geografia e Estatística. Cidades e Estados (2020). www.ibge.gov.br/cidades-e-estado/pa/belem.html
47.
Brasil. IBGE divulga o rendimento domiciliar per capita 2018 (2018). https://agenciadenoticias.ibge.gov.br/agencia-sala-de-imprensa/2013-agencia-de-noticias/releases/23852-ibge-divulga-o-rendimento-domiciliar-per-capita-2018
48.
Brasil. Preços máximos de medicamentos por Princípio Ativo (2016). http://portal.anvisa.gov.br/documents/374947/2829072/LISTA+CONFORMIDADE_201606-20.pdf/af0a54e7-249d-4855-ba9a-419f73249967
49.
Brasil. Cadernos de Informações da Saúde Suplementar – Beneficiários, Operadoras e Planos (2014). www.ans.gov.br/images/stories/Materiais_para_pesquisa/Perfil_setor/Caderno_informacao_saude_suplementar/2014_mes06_caderno_informacao.pdf
50.
Brasil. Banco Central do Brasil. Conversor de Moedas (2020). www.bcb.gov.br/conversao
51.
Instituto Brasileiro de Geografia e Estatística. Pesquisa Nacional por Amostra de Domicílios Continua Trimestral, população por níveis de instrução (2019). https://sidra.ibge.gov.br/tabela/5919
52.
Instituto Brasileiro de Geografia e Estatística. Síntese de Indicadores Sociais: Uma Análise das Condições de vida da População Brasileira (2019). https://biblioteca.ibge.gov.br/visualizacao/livros/liv101678.pdf
53.
Brasil. Sistema Único de Saúde (SUS): estrutura, princípios e como funciona (2020). www.saude.gov.br/sistema-unico-de-saude
54.
Sistema de Informação de Agravos de Notificação (SINAN). Distribuição dos Casos de Doença de Chagas Aguda, segundo UF de residência, 2008 a 2017 (2017). www.saude.gov.br/images/pdf/2019/julho/26/CASOS-AGUDOS-CONFIRMADOS-NO-SINAN-POR-UF-DE-RESID--NCIA--2008-A-2017-.pdf
•• Important reference source associated with the epidemiological scenario of Chagas disease in Brazil.
55.
Brasil. Doença de Chagas Aguda (2020). www2.datasus.gov.br/DATASUS/index.php?area=0203&id=29890013&VObj=http://tabnet.datasus.gov.br/cgi/deftohtm.exe?sinannet/cnv/chagas
•• Important reference source associated with the epidemiological scenario of Chagas disease in Brazil.
56.
Shikanai-Yasuda MA, Carvalho NB. Oral transmission of Chagas disease. Clin. Infect. Dis. 54(6), 845–852 (2012).
57.
Barbosa RL, Dias VL, Pereira KS et al. Survival in vitro and virulence of Trypanosoma cruzi in açaí pulp in experimental acute Chagas disease. J. Food Prot. 75(3), 601–606 (2012).
• Important reference source associated with the scenario of Chagas disease in the Northern of Brazil.
58.
Dias JC, Ramos AN Jr, Gontijo ED et al. II Brazilian Consensus on Chagas Disease, 2015. Epidemiol. Health Serv. 25(spe), 7–86 (2016).
• Important reference source associated with the scenario of Chagas disease in Brazil.
59.
Santos VRCD, Meis J, Savino W et al. Acute Chagas disease in the state of Pará, Amazon Region: is it increasing? Mem. Inst. Oswaldo Cruz 113(5), e170298 (2018).
60.
Brasil. Malária: o que é, causas, sintomas, tratamento, diagnóstico e prevenção (2020). https://saude.gov.br/saude-de-a-z/malaria
61.
Lucas ME, Jeuland M, Deen J et al. Private demand for cholera vaccines in Beira, Mozambique. Vaccine 25(14), 2599–2609 (2007).
62.
Kim D, Canh DG, Poulos C et al. Private demand for cholera vaccines in Hue, Vietnam. Value Health 11(1), 119–128 (2008).
63.
Giuberti AC, Menezes-Filho N. Discrimination of income by gender: a comparison between Brazil and the United States. App. Econ. 9(3), 369–384 (2005).
64.
Gomes MR, Souza SCI. Gender wage asymmetries and the regional approach in Brazil: an analysis according to admission to employment and sectors of activity. Cont. Econ. Mag. 22, 3 (2018).
65.
Abdulkadir BI, Ajayi IO. Willingness to accept malaria vaccine among caregivers of children under 5 in the local government area of Ibadan North, Nigeria. Malaria World J. 6, 2 (2015).
66.
Fundação Oswaldo Cruz. Vacinas (2017). http://chagas.fiocruz.br/vacinas/
67.
Brasil. Sobre o programa (2020). www.saude.gov.br/saude-de-a-z/vacinacao/sobre-o-programa/
68.
Lee BY, Bacon KM, Connor DL, Willig AM, Bailey RR. The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. PLoS Negl. Trop. Dis. 4(12), e916 (2010).
•• Important to complement our knowledge of economic value of a vaccine in Latin America.
Information & Authors
Information
Published In
Pages: 659 - 672
PubMed: 33851872
Copyright
© 2021 Future Medicine Ltd.
History
Received: 4 November 2020
Accepted: 12 March 2021
Published online: 14 April 2021
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Consumer willingness to pay for a hypothetical Chagas disease vaccine in Brazil: a cross-sectional study and the implications. (2021) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0241
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Ana Cristina de Oliveira Pereira, José Duanne Benevides de Lima, Thais Miranda de Castro, Maria Áurea Catarina Passos Lopes, Mariana Alves Benigno, Rosilene Nascimento da Silva Xavier, Marina Layara Sindeaux Benevides, NEGLIGÊNCIA DAS POLÍTICAS PÚBLICAS RELACIONADAS À DOENÇA DE CHAGAS NO BRASIL: REVISÃO DE ESCOPO, RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218, 10.47820/recima21.v7i4.7476, 7, 4, (e747476), (2026).
- Vinícius Gonçalves Nogueira, Edna Afonso Reis, Brian Godman, Antony Paul Martin, Isabella Piassi Dias Godói, Acceptability and willingness to pay for a hypothetical HIV vaccine in Brazil and the implications: a cross-sectional study, Expert Review of Pharmacoeconomics & Outcomes Research, 10.1080/14737167.2024.2384543, 25, 1, (91-100), (2024).
- Francesco Ramponi, Céline Aerts, Paula Sartor, María Jesús Pinazo, Héctor Freilij, Carlos A. Guzmán, Emilio Malchiodi, Elisa Sicuri, Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare, Gaceta Sanitaria, 10.1016/j.gaceta.2022.102275, 37, (102275), (2023).
- Brian Godman, Joseph Fadare, Hye-Young Kwon, Carolina Zampirolli Dias, Amanj Kurdi, Isabella Piassi Dias Godói, Dan Kibuule, Iris Hoxha, Sylvia Opanga, Zikria Saleem, Tomasz Bochenek, Vanda Marković-Peković, Ileana Mardare, Aubrey C Kalungia, Stephen Campbell, Eleonora Allocati, Alice Pisana, Antony P Martin , Johanna C Meyer, Evidence-based public policy making for medicines across countries: findings and implications for the future, Journal of Comparative Effectiveness Research, 10.2217/cer-2020-0273, 10, 12, (1019-1052), (2021).
- Isabella Piassi Dias-Godói, Túlio Tadeu Rocha Sarmento, Edna Afonso Reis, Ludmila Peres Gargano, Brian Godman, Francisco de Assis Acurcio, Juliana Alvares-Teodoro, Augusto Afonso Guerra Júnior, Cristina Mariano Ruas, Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications, Expert Review of Pharmacoeconomics & Outcomes Research, 10.1080/14737167.2021.1931128, 22, 1, (119-129), (2021).